Loading organizations...
Orakl Oncology develops an AI-native predictive platform designed to transform cancer drug development. This platform integrates patient-derived biology, advanced artificial intelligence, and real-world data to identify novel drug targets and forecast patient responses. Their technical approach centers on creating "Patient Tumor Avatars" from patient-derived organoids, which are then enriched with comprehensive multimodal genomic, transcriptomic, and clinical datasets, and utilizing a proprietary predictive engine capable of zero-shot prediction for clinical trial outcomes.
Orakl Oncology was established in 2023 as a spin-off from the Gustave Roussy Institute of Oncology. The company was co-founded by Fanny Jaulin, PhD, who serves as CEO, Diane-Laure Pagès, PhD, the COO, and Gustave Ronteix, PhD, the CTO. Their collective insight stemmed from the intersection of biological research and data science, recognizing the potential to leverage patient-specific biological models and AI to address the complexities and inefficiencies inherent in traditional cancer drug discovery.
The company primarily serves pharmaceutical companies, assisting them in de-risking clinical trials and accelerating drug approvals by identifying promising novel targets. They also partner with hospitals to expand their collection of living tumor avatars, thereby capturing the complexity of cancer and patient heterogeneity. Orakl Oncology’s overarching vision is to improve and expand the therapeutic arsenal available to cancer patients, ultimately making drug development more efficient and effective in the fight against cancer.
Orakl Oncology has raised $18.1M across 3 funding rounds.
Orakl Oncology has raised $18.1M in total across 3 funding rounds.
Orakl Oncology does not appear to be a distinct technology company based on available information; the query likely refers to Oracle's oncology-focused initiatives within Oracle Health and Life Sciences, which develops AI-powered electronic health records (EHRs), clinical tools, and data platforms tailored for cancer care.[1][2][3] Oracle serves cancer centers, researchers, clinicians, and patients by addressing gaps in oncology workflows, such as integrating clinical and genomic data for personalized medicine, streamlining clinical trials, and enabling AI-driven decision support.[1][3] This solves critical problems like fragmented data, inefficient trial matching, and administrative burdens in cancer care, with strong growth momentum evidenced by partnerships like the November 2025 collaboration with the Cancer Center Informatics Society (Ci4CC) and engagement from over 100 cancer sites exploring Oracle's platforms.[1][3]
Oracle's oncology efforts leverage its EHR and electronic data capture systems to pioneer precision oncology, real-world evidence, and ambient patient experiences, positioning it as a leader in AI-enhanced cancer innovation amid rising demand for specialized tools.[2][3]
Oracle Health and Life Sciences evolved its oncology focus through strategic acquisitions and internal development, notably integrating Cerner (now Oracle Cerner) to build comprehensive EHR capabilities, with oncology gaining traction via recent AI advancements.[3][4] Key figures include Seema Verma, EVP and General Manager, who has driven the push into specialty care like oncology, highlighting clinician feedback on inadequate existing systems.[3] The idea for oncology-specific tools emerged from demands at academic and community cancer centers for better data precision, trial eligibility matching via genomic markers, and workflow support, culminating in the non-binding Ci4CC partnership announced at their 2025 Miami Beach symposium to co-design an oncology-optimized EHR.[1][2]
Early traction includes rapid adoption of Oracle's Clinical AI Agent by nearly 10,000 clinicians across specialties for documentation and summaries, with oncology sites reporting "early wins" in AI trial matching and over 100 engagements signaling pivotal momentum.[3]
These elements provide superior developer/clinician experience through intuitive data access, ambient interfaces, and regulatory-aligned workflows.[3][4]
Oracle rides the AI-precision oncology wave, capitalizing on trends like genomic data explosion, next-gen clinical trials, and personalized therapies amid cancer's status as a leading global killer.[1][2][6] Timing is ideal post-2025 Ci4CC alliance and FDA approvals for AI agents, aligning with US government interoperability pushes (e.g., CMS frameworks, FHIR exchange) and projected gene therapy spending growth to $25.3B by 2026.[3][4][6] Market forces favoring Oracle include clinician burnout, demand for real-world evidence, and complex supply chains in life sciences, where its end-to-end solutions streamline trials, safety monitoring, and resource optimization.[3][6]
Oracle influences the ecosystem by fostering collaborations that turn data into actionable insights, redefining cancer care delivery and research scalability.[1][7]
Oracle's oncology push positions it for dominance in 2026 with broader AI agents across clinical operations, oncology-specific EHR rollouts, and ambient patient portals mimicking modern tech experiences.[3][4] Trends like AI-drug development, nationwide data sharing, and electronic prior authorizations will propel growth, potentially evolving Oracle from vendor to indispensable partner via "partner-first" strategies.[4][7] As Ci4CC initiatives mature, expect deeper ecosystem influence through incubated precision platforms, tying back to its core strength: transforming fragmented oncology data into life-saving knowledge.[1][2]
Orakl Oncology has raised $18.1M across 3 funding rounds. Most recently, it raised $12.0M Seed in December 2024.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Dec 1, 2024 | $12M Seed | Singular | Adjacent, Cavalry Ventures, Founderful, Hardware Club, Nina Capital, Speedinvest, Verve Ventures, Christopher Muhr, Hanno Heintzenberg, Lukas Pieczonka | Announced |
| Oct 4, 2023 | $3.1M Venture Round | Speedinvest | — | Announced |
| Oct 1, 2023 | $3M Seed | — | Founderful, Hardware Club, Nina Capital, Singular, Speedinvest, Verve Ventures | Announced |
Orakl Oncology has raised $18.1M in total across 3 funding rounds.
Orakl Oncology's investors include Singular, Adjacent, Cavalry Ventures, Founderful, Hardware Club, Nina Capital, Speedinvest, Verve Ventures, Christopher Muhr, Hanno Heintzenberg, Lukas Pieczonka.
